Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 75.68 USD 2.15% Market Closed
Market Cap: 13.5B USD
Have any thoughts about
Insmed Inc?
Write Note

Insmed Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Insmed Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Insmed Inc
NASDAQ:INSM
Net Issuance of Common Stock
$910.2m
CAGR 3-Years
44%
CAGR 5-Years
27%
CAGR 10-Years
30%
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-10%
CAGR 5-Years
16%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$782m
CAGR 3-Years
11%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$243.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Insmed Inc
Glance View

Market Cap
12.6B USD
Industry
Biotechnology

Insmed Inc. is a biopharmaceutical company on a mission to transform the lives of patients with severe and rare diseases, particularly those related to lung and infectious conditions. Founded in 1988, Insmed has carved out a niche in the biotechnology landscape with its innovative approach to drug development. The company's flagship product, Arikayce, has gained approval for the treatment of nontuberculous mycobacterial (NTM) lung infections, demonstrating its commitment to addressing unmet medical needs. With a robust pipeline of therapeutic candidates focusing on rare diseases, Insmed is not just another player in the biopharma space; it is dedicated to solving complex health challenges where conventional therapies have fallen short. Investors should take note of Insmed’s strategic direction and strong market position. The company is actively expanding its reach through ongoing clinical trials for its next generation therapies, which aim to target diseases with limited treatment options. With a solid financial foundation and partnerships that bolster its research capabilities, Insmed is poised for growth. As healthcare organizations increasingly prioritize personalized medicine and innovative treatments, Insmed's willingness to tackle rare conditions places it on a promising trajectory. For investors, this represents an opportunity not just in terms of potential financial returns, but also in contributing to advancements in healthcare that can have a meaningful impact on patients' lives.

INSM Intrinsic Value
55.56 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Insmed Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
910.2m USD

Based on the financial report for Jun 30, 2024, Insmed Inc's Net Issuance of Common Stock amounts to 910.2m USD.

What is Insmed Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
30%

Over the last year, the Net Issuance of Common Stock growth was 164%. The average annual Net Issuance of Common Stock growth rates for Insmed Inc have been 44% over the past three years , 27% over the past five years , and 30% over the past ten years .

Back to Top